Larynx liposarcoma

disease
On this page

Also known as laryngeal liposarcomalip larynx sarcomaliposarcoma of larynxliposarcoma of the larynx

Summary

Larynx liposarcoma (MONDO:0003588) is a disease. A subtype of laryngeal sarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namelarynx liposarcoma
Mondo IDMONDO:0003588
DOIDDOID:5696
NCITC6021
UMLSC1334372
MedGen235252
GARD0023572
Anatomy (UBERON)UBERON:0001737
Is cancer (heuristic)no

Also known as: laryngeal liposarcoma · larynx liposarcoma · lip larynx sarcoma · liposarcoma of larynx · liposarcoma of the larynx

Disease family

This is a subtype of laryngeal sarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumorneoplastic disease or syndromeneoplasmcancerrespiratory system cancerlarynx cancerlaryngeal sarcomalarynx liposarcoma

Related subtypes (1): laryngeal leiomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.